TrialResults-center.org
Search
Menu
Home
Search
Recent trials
Browse pathology
Browse treatment
About us
Enoxaparin
LMWH
systematic review
meta-analysis
network meta-analysis
Clexane - Lovenox
Select
acute coronary syndrome
acute myocardial infarction
heart failure
percutaneous coronary intervention
pulmonary embolism
superficial thrombophlebitis
thrombosis prevention
venous thrombosis
extended LMWH
extended prophylaxis
long term LMWH
Low molecular weight heparin
once daily LMWH
Prophylactic LMWH
short term LMWH
Therapeutic LMWH
vs anticoagulant
vs heparin
vs oral anticoagulant
vs placebo or control
vs placebo or no treatment
vs Dextran
vs LMWH
vs twice daily LMWH
vs UFH
vs Unfractionated heparin
vs unfractioned heparin
pdf
Filter
hide ongoing
show ongoing
hide ongoing
all ROB
Show all trials
Show only trial at low risk of bias
Hide exploratory trials
all results
Show all trials
Show only trial with conclusive result
Group by
Group by...
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
MA
in first
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in second
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in third
Description
Synopsis
Comparison
Treatments
Patients
Characteristics
Method
Risk of bias
References
None
Tools
Indexation
Results
Global trial result
Main results
All results
All result tag
NCT results
Major bleeding (54)
All cause death (49)
Bleeding (33)
Minor bleeding (29)
asymptomatic DVT (22)
Symptomatic pulmonary embolism (22)
myocardial infarction (fatal and non fatal) (18)
Symptomatic venous thromboembolism (DVT, PE) (17)
net benefit (16)
Recurrent thromboembolic event (13)
wound haematoma / infection (13)
transfusion (13)
fatal pulmonary embolism (11)
major or clinically relevant non-major bleeding (10)
total VTE and all-cause mortality (10)
MACE (10)
stroke (fatal and non fatal) (9)
Venous thromboembolism (9)
death, MI, unplanned revascularization (9)
Unplanned revascularisation for ischaemia (9)
Symptomatic deep-vein thrombosis (9)
Deep vein thrombosis (8)
death, myocardial infarction, or recurrent at 30 days (7)
death at 30 days (7)
myocardial infarction at 30 days (7)
Drop in platelet count of 50% (7)
myocardial infarction or death (7)
death, myocardial infarction, or recurrent at 14 days (7)
recurrent angina (7)
Revascularization (7)
death at 30 days (7)
reinfarction (7)
In-hospital death (7)
reinfarction at 30 days (7)
Deaths or MI (7)
proximal deep-vein thrombosis (6)
pulmonary embolism (symptomatic and asymptomatic) (6)
Venous thromboembolism or death (6)
VTE during active anticoagulant treatment (6)
VTE during follow-up after active anticoagulant treatment (6)
puylmonary embolism (6)
recurrent DVT (6)
proximal DVT (3)
non-fatal pulmonary embolism (3)
Recurrent DVT/DVT extension (symptomatic) (3)
recurrent VTE (3)
Fatal bleeding (3)
Thrombocytopenia (3)
death at 3 months (3)
Long term death (3)
distal DVT (3)
Extension and/or recurrence of SVT (2)
Heparin-induced thrombocytopenia (2)
Pain disappearance (2)
Thrombus extension (2)
Short term haemorrhage (2)
symptomatic venous thromboembolism at the end of treatment (2)
recurrent symptomatic venous thromboembolism and death at the end of treatment (2)
Recurrent Symptomatic Venous Thromboembolism or death (2)
Venous thromboembolism end of treatment (2)
Serious adverse event (1)
exacerbation of heart failure (1)
All-cause hospitalisation (1)
cardiovascular events (1)
Cardiovascular death (1)
stent thrombosis (1)
Options
Numeric
bar chart
forest plot
medians
Trial
Studied trt
Control trt
patients
tags
ROB
Trial result
Major bleeding
All cause death
acute coronary syndrome
RESCUE
NCT
enoxaparin
unfractionated heparin
-
EVET, 2005
enoxaparin
tinzaparin
suggesting
-50%
TIMI 11 B (short term), 1998
enoxaparin
UFH (on top of aspirin)
Low risk of bias
suggesting
52%
-17%
SYNERGY, 2005
NCT
enoxaparin
UFH (on top of aspirin)
negative
19%
4%
ESSENCE, 1997
enoxaparin
UFH (on top of aspirin)
Low risk of bias
suggesting
-7%
-3%
INTERACT, 2006
enoxaparin
UFH (on top of aspirin)
suggesting
-60%
-42%
TIMI 11 B (long term), 1998
enoxaparin
UFH (on top of aspirin)
Low risk of bias
negative
90%
-4%
acute myocardial infarction
AMI-SK, 2002
Enoxaparin
placebo
Low risk of bias
-
ASSENT 3, 2001
Enoxaparin
UFH
suggesting
ASSENT 3 Plus, 2003
Enoxaparin
UFH
negative
ENTIRE-TIMI 2, 2002
Enoxaparin
UFH
suggesting
Baird, 2002
Enoxaparin
UFH
negative
HART II, 2001
Enoxaparin
UFH
negative
heart failure
THE-PRINCE (Kleber), 2003
enoxaparin
UFH
-
percutaneous coronary intervention
Drozd, 2001
enoxaparin
UFH
negative
Dudek b (enox alone), 2000
enoxaparin
UFH
-
Dudek, 2000
enoxaparin
UFH
negative
STEEPLE, 2006
NCT
enoxaparin
UFH
Risk of bias
-
Galeote, 2001
enoxaparin
UFH
negative
CRUISE, 2003
enoxaparin
UFH
Exploratory
negative
Rabah, 1999
enoxaparin
UFH
Exploratory
negative
ATOLL, 2010
enoxaparin
UFH
Risk of bias
-
Dubek b (+abciximal), 2001
enoxaparin+abciximab
UFH
-
pulmonary embolism
PREPIC, 1998
Enoxaparin
unfractionated heparin
Risk of bias
negative
Merli sub group, 2001
Enoxaparin
unfractionated heparin
Exploratory
negative
superficial thrombophlebitis
STENOX (enoxaparin 1.5mg/hg), 2003
enoxaparin
placebo
-
Stenox (enoxaparin 40mg), 2003
enoxaparin
placebo
-
thrombosis prevention
Canata, 2003
enoxaparin
control
Exploratory
negative
Warwick, 1995
enoxaparin
no treatment
hip surgery
negative
Ho [43]
enoxaparin
no treatment
negative
Samama, 1997
enoxaparin
placebo
hip surgery
Low risk of bias
suggesting
Kalodiki, 1996
enoxaparin
placebo
hip surgery
Low risk of bias
-
MEDENOX, 1999
Enoxaparin
placebo
medical patients
Low risk of bias
suggesting
48%
-26%
Lederle, 2006
Enoxaparin
placebo
medical patients
Low risk of bias
negative
-60%
Agnelli, 1998
enoxaparin
placebo
suggesting
Melon, 1987
enoxaparin
placebo
negative
LIFENOX, 2011
NCT
enoxaparin
placebo
medical patients
Low risk of bias
negative
40%
0%
LeGagneux , 1987
enoxaparin
placebo
negative
36%
Turpie, 1986
enoxaparin
placebo
hip surgery
Low risk of bias
suggesting
-100%
Leclerc, 1991
enoxaparin
placebo
knee surgery
Low risk of bias
suggesting
DES Group , 1991
enoxaparin
Dextran
hip surgery
suggesting
∞%
Comp, 2001
out of hospital Enoxaparin
standard prophylaxis
suggesting
-100%
-100%
Planes, 1996
out of hospital Enoxaparin
standard prophylaxis
negative
Bergqvist, 1996
out of hospital Enoxaparin
standard prophylaxis
suggesting
Bergmann and Neuhart, 1996
enoxaparin
UFH
medical patients
Low risk of bias
negative
-10%
Lechler, 1996
enoxaparin
UFH
medical patients
Low risk of bias
negative
-36%
Kleber, 2003
enoxaparin
UFH
medical patients
negative
-40%
Nurmohamed, 1995
enoxaparin
unfractionated heparin
general surgery
-
ENOXACAN, 1997
enoxaparin
unfractionated heparin
abdominal surgery
-
Gonzalez, 1996
enoxaparin
unfractionated heparin
abdominal surgery
-
McLeod (Canadian), 1995
enoxaparin
unfractionated heparin
abdominal surgery
-
Gazzaniga (ISG), 1993
enoxaparin
unfractionated heparin
general surgery
-
Kaaja, 1992
enoxaparin
unfractionated heparin
gynaecological surgery
-
Samama 3, 1988
enoxaparin
unfractionated heparin
general surgery
negative
-8%
∞%
Samama 2, 1988
enoxaparin
unfractionated heparin
general surgery
negative
∞%
∞%
Samama 1, 1988
enoxaparin
unfractionated heparin
general surgery
negative
-1%
∞%
Planes , 1988
enoxaparin
Unfractionated heparin
hip surgery
suggesting
Levine , 1991
enoxaparin
Unfractionated heparin
hip surgery
negative
venous thrombosis
Veiga, 2000
Enoxaparin
acenocoumarol
Risk of bias
negative
González-Fajardo, 2008
Enoxaparin
coumarin
Risk of bias
-
Cesarone, 2003
extended enoxaparin
standard treatment
negative
-33%
Deitcher, 2006
extended enoxaparin
standard treatment
negative
204%
1%
Meyer, 2002
extended enoxaparin
standard treatment
negative
-56%
-20%
Pini, 1994
Enoxaparin
warfarin
Risk of bias
negative
Gonzalez-Fajardo, 1999
Enoxaparin
warfarin
Risk of bias
suggesting
Meyer, 2002
Enoxaparin
warfarin
Risk of bias
negative
Deitcher, 2003
Enoxaparin
warfarin
Risk of bias
negative
Merli, 2001
once daily enoxaparin
twice daily enoxaparin
Low risk of bias
negative
65%
Merli (once daily vs UFH), 2001
once daily enoxaparin
UFH
Low risk of bias
negative
19%
Simonneau et al , 1993
Enoxaparin
unfractionated heparin
negative
50%
×
Modal title